OncoTherapy Science Reports Q3

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 6, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

OncoTherapy Science Reports Q3 Non-operating Expenses

Source disclosure: February 06, 2026 OncoTherapy Science,Inc. [4564.T] TOKYO, Feb 06 (Pulse News Wire) – Oncotherapy Science,inc. (4564.T) reported non-operating expenses for the third quarter of its fiscal year ending March 2026. The company recorded issuance costs related to the distribution of shares resulting from the exercise of warrants amounting to ¥23 million. In addition, OncoTherapy Science stated that while it has yet to disclose its full-year forecast for the fiscal year